Stem cell treatment shows promise for stubborn leg wounds
NCT ID NCT06489028
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 3 trial tests a donor stem cell treatment called Allo-APZ2-CVU for people with chronic venous leg ulcers that haven't healed with standard therapy. About 250 adults with ulcers between 1 and 25 cm² will receive either the cell therapy or a placebo applied directly to the wound. The main goal is to see if the treatment leads to complete wound closure lasting at least two weeks.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Allo-APZ2-CVU (a type of donor stem cells applied to the wound)
What this could lead to
If it works, this could offer a new treatment option for people with chronic leg ulcers that haven't healed with standard care.
What could go wrong
This is still being tested in a late-stage trial, so results are not yet confirmed. The treatment may not work better than placebo, and there could be side effects from the cell therapy.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for VENOUS LEG ULCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
RHEACELL Clinical Trial Site
Hialeah, Florida, 33012, United States
-
RHEACELL Clinical Trial Site
Miami, Florida, 33136, United States
-
RHEACELL Clinical Trial Site
Boston, Massachusetts, 02114, United States
-
RHEACELL Clinical Trial Site
Minneapolis, Minnesota, 55455, United States
-
RHEACELL Clinical Trial Site
Multiple Locations, Austria
-
RHEACELL Clinical Trial Site
Multiple Locations, Czechia
-
RHEACELL Clinical Trial Site
Multiple Locations, France
-
RHEACELL Clinical Trial Site
Several Locations, Germany
-
RHEACELL Clinical Trial Site
Multiple Locations, Hungary
-
RHEACELL Clinical Trial Site
Multiple Locations, Italy
-
RHEACELL Clinical Trial Site
Multiple Locations, Netherlands
-
RHEACELL Clinical Trial Site
Multiple Locations, Poland
-
RHEACELL Clinical Trial Site
Multiple Locations, Slovakia
-
RHEACELL Clinical Trial Site
Multiple Locations, Sweden
-
RHEACELL Clinical Trial Site
Multiple Locations, United Kingdom